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Nearly all systems in the body are affected by the meta-
bolic disarrangement of diabetes mellitus. Consequently,
a serious signaling pathway may develop that can
potentially lead to several adverse complications. Dia-
betic otopathy (DO) is a clinical syndrome characterized
by hearing impairment due to the toxic effect of diabetes
mellitus. Evidence-based studies have indicated a signifi-
cant relationship between vestibular and/or auditory
disorders and diabetes mellitus. A screening test for DO
has been suggested in all diabetic patients with long-
standing disease. Further clinical trials are warranted to
explore the molecular mechanisms of DO.
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Diabetes mellitus is the most common non-communicable
disease in urban areas, where modifiable risk factors are still
rampant.1 Diabetes mellitus is characterized by increased
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many physiological systems and results in complications
through the modification of various cellular events in the
body.2
Societal consequences of diabetes are very costly to our
health care system.3 It has been estimated that by 2025 there
will be an astounding 300 million diabetic individuals in the
world, twice as many as in 2000.4
Diabetes mellitus selectively damages cells that are unable
to reduce the transport of glucose inside cells when they are
exposed to hyperglycemia, such as mesangial cells and
endothelial cells, leading to high glucose inside the cell.5 This
effect is important because it explains why diabetic patients
showed a marked inability of cells to utilize glucose, as well
as problems with insulin secretion or secretion patterns.6
Nearly all of the body’s systems are affected by the
metabolic disarrangement of diabetes mellitus, which
results in many painful, serious and life-threatening com-
plications, such as diabetic retinopathy,7 foot and trophic
ulcers,8 neuropathy,9 nephropathy,10 osteopathy,11
peripheral arterial disease,12 coronary artery disease,13
colorectal malignancy,14 acute pancreatitis and biliary
diseases.15Pathophysiological mechanisms
Hyperglycemia initiates many pathophysiological path-
ways in the nervous system as a result of apoptosis, nerve
energy deficits, intracellular calcium excitotoxicity, the for-
mation of glycosylated products, oxidative stress hypoxia
and ischemia, which damage many nerve components.16 The
first damage mechanism that was discovered was increased
polyol pathway flux, described in peripheral nerves in
1966.17 Damage to myelin sheaths and other nerve
components in the peripheral nervous system have been
found as a result of hyperglycemia.18
Hearing requires energy for signal processing. The audi-
tory system may be a target of diabetes mellitus. Increasedy. This is an open access article under the CC BY-NC-ND license
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disrupt the cochlea both anatomically and physiologically.
Diabetic Otopathy (DO) is the presence of symptoms and
signs of vestibular and/or auditory disorders (otopathy) in
people with diabetes after the exclusion of other causes.19
Manifestations of DO include dizziness, vertigo, tinnitus
and hearing loss.20 DO is considered an under-recognized
complication of diabetes mellitus21 because patients with
DO usually look for an audiologist to diagnose and treat
the disorder. Previous studies have shown that the
prevalence of otopathy was higher in diabetic patients
compare with non-diabetic patients.22 DO had been
debated for many years; the first case report of DO was
documented in 1857.23
DO is an early complication of diabetes mellitus, and it is
related to the duration of the disease and the degree of meta-
bolic control.24,25 It is usually subclinical and can be detected
early by accurate and objective audiometric methods.26
A formal study conducted by Parving in 1990 in patients
with long term type 1 diabetes found that auditory tests
responses were abnormal in 40% of patients.27
DO is multifactorial, and the pathogenesis of DO has been
explained in terms of auditory neuropathy, microangiopathy
of the cochlea and encephalopathy,28 which can affect the
hearing pathway from the labyrinth to the cortical areas.29
Many authors agree that DO is an early manifestation of
diabetic neuropathy and can lead to sensorineural hearing
loss.26 Increases in blood glucose and metabolic end
products can easily lead to toxicity affected by neuropathy.
Aladag (2009) reported that the formation of protein
oxidation as part of oxidative stress appears to be more
important than lipid peroxidation in the pathogenesis of
DO.28
High blood glucose increases the intracellular accumula-
tion of sorbitol (a part of the polyol pathway), which slows
nerve conduction velocity30 and may be related to the
immune, ischemic and metabolic changes mediated by
diabetes.31 The cochlea contains Na/K/ATPase enzymes,
and during diabetes, hyperglycemia down-regulates Na/K/
ATPase, causing elevated intracellular Naþ and extracellular
Kþ and Caþþ excitotoxicity.32 Nitric oxide plays an
important role in regulation of the vascular endothelium of
the auditory system. Nitric oxide is located in key cochlear
blood vessels. It was determined that the metabolic changes
during diabetes impair the production of nitric oxide or/
and cause vasodilation that limits blood supply to certain
areas of the auditory system. Once ischemia is present, a
cascade of mechanisms are initiated, such as apoptosis and
excitotoxicity, due to elevated intracellular Caþþ and
damaged DNA.33,34
An association between lipid disorders and DO due
to hyperinsulinemia and insulin resistance has been
reported.35 Many studies have been described in
patients with vertigo, stressing their higher risk for
atherosclerosis.36e38 A published autopsy report of a patient
with recurring vertigo episodes found atherosclerotic
vasculopathy of the anterior vestibular artery, confirming
the hypothesis that insulin and/or glucose disorders affect
microcirculation.39 Diabetes also interferes with nutrient
transportation through thickened and narrowed vessels and
acts indirectly through causing degenerative changes in the
vestibulocochlear nerve.40Regarding hearing, among the most serious metabolic
changes of diabetes mellitus is microangiopathy. It plays an
important role in the vasculature of the auditory system.
Studies have reported important changes, such as increased
basement membrane thickening and porosity of the endo-
thelium, due to the upregulation of vascular endothelial
growth factor and increased vascular permeability factor.
This results in increased permeability of the endothelium,
which may lead to changes in auditory electrolyte homeo-
stasis within the endolymph and interfere with hair cell
transduction and signal transmission.41
The metabolic changes of diabetes mellitus resulting from
deposits of advanced glycation end-products into collagen in
many areas of the peripheral auditory system18 lead to
abnormal post-translational protein modifications, causing
articulation with the hair cells and deficits in sound
transduction.42
Endolymph is a medium wherein the intracellular envi-
ronment depends on glucose for cellular function. Utilizing
other substrates as alternative sources of energy to maintain
the endolymph during diabetes mellitus may be another
important cause of DO.43
Histological studies on diabetic patients have reported
significantly greater hearing loss with basilar membrane
microangiopathy and significantly lower percentages of his-
tologically normal hair cells and stria vascularis cells, which
suggest that diabetic sensorineural hearing loss results from
microangiopathic involvement of the endolymphatic sac
and/or basilar membrane vessels.44 Therefore, diabetic
patients must be considered at risk for vestibular and/or
auditory disorders.45
Conclusions
DO is one complication of diabetes mellitus. Along with
renal, ophthalmic and cardiovascular screenings, diabetic
patients should undergo regular auditory screenings. Further
studies are needed to explore the molecular mechanisms of
DO and to clarify the relationship between the severity of
diabetes and the prevalence of DO.
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